Scholarlink

Purpose <p>To assess the diagnostic performance of tumor blood volume (TBV) derived from T1 dynamic contrast-enhanced (DCE) MRI and compare it with ADC and SUV<sub>max</sub> in distinguishing recurrence from post-treatment changes.</p> Methods <p>This retrospective study included 73 patients with 75 focal contrast-enhancing lesions identified on surveillance MRI. Normalized TBV (nTBV<sub>mean</sub>) was calculated from high temporal resolution DCE-MRI using the spinal cord as a reference. The 3D ROI analysis of ADC<sub>mean</sub> and SUV<sub>max</sub> values were obtained from DWI and <sup>18</sup>F-FDG-PET/CT, respectively. Diagnostic performances were evaluated using multivariate logistic regression analyses, with area under the receiver operating characteristic curve (AUROC) comparisons.</p> Results <p>Among the 75 lesions, 38 were recurrence and 37 were post-treatment changes. ADC<sub>mean</sub> and SUV<sub>max</sub> were significantly different between groups (<i>p</i> &lt; 0.001), while nTBV<sub>mean</sub> was higher in recurrence without statistical significance (<i>p</i> = 0.11). The AUROC of ADC<sub>mean</sub>, SUV<sub>max</sub>, and nTBV<sub>mean</sub> were 0.94, 0.88, and 0.60 respectively. The combination of ADC<sub>mean</sub> and SUV<sub>max</sub> yielded the highest AUROC (0.99), with ADC<sub>mean</sub> remaining the most robust predictor. TBV offered complementary value when ADC maps were degraded by susceptibility artifacts.</p> Conclusions <p>ADC<sub>mean</sub> and SUV<sub>max</sub> showed excellent performance in differentiating recurrence from post-treatment changes. TBV maps may offer complementary diagnostic value in cases with compromised ADC quality due to artifacts.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Diagnostic performance of multiparametric imaging markers in differentiating local recurrence from post-treatment change in head and neck cancer surveillance

  • 期刊论文

  • 发表日期：

    2026年1月17日

查看全文
  • Soy Chang,
  • Ji Young Lee,
  • Kook-Jin Ahn,
  • Ilah Shin,
  • Minkook Seo,
  • Jinhee Jang,
  • Bum Soo Kim

摘要

Purpose

To assess the diagnostic performance of tumor blood volume (TBV) derived from T1 dynamic contrast-enhanced (DCE) MRI and compare it with ADC and SUVmax in distinguishing recurrence from post-treatment changes.

Methods

This retrospective study included 73 patients with 75 focal contrast-enhancing lesions identified on surveillance MRI. Normalized TBV (nTBVmean) was calculated from high temporal resolution DCE-MRI using the spinal cord as a reference. The 3D ROI analysis of ADCmean and SUVmax values were obtained from DWI and 18F-FDG-PET/CT, respectively. Diagnostic performances were evaluated using multivariate logistic regression analyses, with area under the receiver operating characteristic curve (AUROC) comparisons.

Results

Among the 75 lesions, 38 were recurrence and 37 were post-treatment changes. ADCmean and SUVmax were significantly different between groups (p < 0.001), while nTBVmean was higher in recurrence without statistical significance (p = 0.11). The AUROC of ADCmean, SUVmax, and nTBVmean were 0.94, 0.88, and 0.60 respectively. The combination of ADCmean and SUVmax yielded the highest AUROC (0.99), with ADCmean remaining the most robust predictor. TBV offered complementary value when ADC maps were degraded by susceptibility artifacts.

Conclusions

ADCmean and SUVmax showed excellent performance in differentiating recurrence from post-treatment changes. TBV maps may offer complementary diagnostic value in cases with compromised ADC quality due to artifacts.